Preeclampsia Severe Clinical Trial
Official title:
Transorbital Ultrasound Measurement of Optic Nerve Sheath Diameter Between Pregnant Women With Severe Preeclampsia and Normal Gestations. Prospective, Controlled Trial.
Verified date | April 2023 |
Source | Saint Thomas Hospital, Panama |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The neurological alterations associated with preeclampsia depend on cerebral autoregulation, a theory that outlines the mechanisms by which the nervous system controls cerebral perfusion. However, with the loss of autoregulation, increased blood flow, edema and eventually increased intracranial pressure are triggered and may be translated into neurological manifestations such as symptoms of vasospasm, one of the criteria for severity in preeclampsia. Nervous system manifestations frequently found in preeclampsia are headache, blurred vision, scotomas and hyperreflexia. Although uncommon, temporary blindness (lasting a few hours to a week) may also accompany severe preeclampsia and eclampsia. The optic nerve, as part of the central nervous system, is surrounded by cerebrospinal fluid and dura mater, which forms the optic nerve sheath. Due to the connection with the intracranial subarachnoid space, the diameter of the optic nerve sheath is influenced by variations in cerebrospinal fluid pressure. Increased intracranial pressure is transmitted to the subarachnoid space surrounding the optic nerve, causing its expansion. Recent studies suggest that an optic nerve sheath diameter greater than 5 mm correlates 100% with ICP (intracerebral pressure) greater than 20 mm Hg. Due to the simple nature of the test and the limited time required to perform it, it is an ideal non-invasive test to assess changes in mental status, severe headache, and to take the necessary measures aimed at reducing intracranial pressure. The diagnosis of elevated intracranial pressure is challenging and critical, because early recognition and treatment are essential to prevent brain damage or death since preeclampsia with severe data remains one of the most frequent complications in our institution. These values are not taken from the obstetric population, so this study proposes the description of a standard value for the pregnant population. There are few studies that describe a value to help us define cases of this pathology and correlate it with the signs and symptoms of severity in patients with preeclampsia.
Status | Completed |
Enrollment | 100 |
Est. completion date | January 31, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 15 Years to 44 Years |
Eligibility | Inclusion Criteria: - Age between 15-44 years. - Gestational age between 34-40 weeks of gestation. Exclusion Criteria: - Eye disease (Glaucoma, diabetic neuropathy, optic neuritis). - Nervous disorders. - Psychiatric disorders - Diabetes |
Country | Name | City | State |
---|---|---|---|
Panama | Saint Thomas H | Panama |
Lead Sponsor | Collaborator |
---|---|
Saint Thomas Hospital, Panama |
Panama,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Optic nerve sheet measurement | The diameter of the optic nerve sheath was measured three millimeters behind the eyeball, and one axis perpendicular to the optic nerve. Three measurements were taken in each eye. The resulting six measurements were averaged to give a mean of the optic nerve sheet measurement, to minimize measurement variability. | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04243278 -
Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC)
|
Early Phase 1 | |
Not yet recruiting |
NCT03318211 -
Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial
|
Phase 4 | |
Recruiting |
NCT03761888 -
Nicardipine and Labetalol Effects on Cerebral Hemodynamics in Preeclampsia
|
||
Not yet recruiting |
NCT06373367 -
Preeclampsia Educational Program Study (PrEPS)
|
N/A | |
Not yet recruiting |
NCT04855513 -
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial
|
N/A | |
Not yet recruiting |
NCT05232994 -
Metformin and Esomeprazole For Preterm Pre-eclampsia
|
Phase 1 | |
Completed |
NCT04392375 -
Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor
|
Phase 4 | |
Recruiting |
NCT03978767 -
Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial
|
Phase 2 | |
Completed |
NCT04236258 -
Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period
|
Phase 4 | |
Completed |
NCT04756661 -
Uterotonics for Severe Preeclampsia
|
N/A | |
Active, not recruiting |
NCT04660032 -
Nudge to Drive Transitions of Care
|
N/A | |
Completed |
NCT04103489 -
The Use of Eculizumab in HELLP Syndrome
|
Phase 1 | |
Enrolling by invitation |
NCT04794855 -
Risk Prediction Model of Preeclampsia
|
||
Recruiting |
NCT04311749 -
Expanded NIPT for Pregnancy Complications
|
||
Active, not recruiting |
NCT06359015 -
Metformin and Esomeprazole in Preterm Pre-eclampsia
|
Phase 4 | |
Recruiting |
NCT05610774 -
Optic Nerve Sheath Diameter in Pre-Eclamptic Parturient Receiving Magnesium Sulfate Combined With Dexmedetomidine
|
N/A | |
Completed |
NCT03815110 -
Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification
|
||
Completed |
NCT03210350 -
Effect of Magnesium Sulphate on the Intracranial Pressure of Preeclamptic Patients
|
||
Completed |
NCT03451266 -
Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia
|
Phase 1 | |
Active, not recruiting |
NCT06360601 -
Intravenous Labetalol Versus Hydralazine in Preeclampsia
|
Phase 1/Phase 2 |